Literature DB >> 26434947

Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.

Christopher C Stobart1,2, Martin L Moore1,2.   

Abstract

Vaccines represent one of the greatest contributions of the scientific community to global health. Yet, many pathogens remain either unchallenged or inadequately hindered by commercially available vaccines. Respiratory viruses pose distinct and difficult challenges due to their ability to rapidly spread, adapt, and modify the host immune response. Considerable research has been directed to understand the role of respiratory virus immunomodulatory proteins and how they influence the host immune response. We review here efforts to develop next-generation vaccines through targeting these key immunomodulatory genes in influenza virus, coronaviruses, respiratory syncytial virus, measles virus, and mumps virus.

Entities:  

Keywords:  coronavirus; immunology; influenza; measles; mumps; next-generation vaccines; pathogenesis; respiratory syncytial virus; respiratory viruses

Mesh:

Substances:

Year:  2015        PMID: 26434947      PMCID: PMC4889331          DOI: 10.1586/14760584.2015.1095096

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  127 in total

1.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Jeryl Lynn strain live attenuated mumps virus vaccine. Durability of immunity following administration.

Authors:  R E Weibel; J Stokes; E B Buynak; M B Leagus; M R Hilleman
Journal:  JAMA       Date:  1968-01-01       Impact factor: 56.272

3.  Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.

Authors:  Sunee Techaarpornkul; Peter L Collins; Mark E Peeples
Journal:  Virology       Date:  2002-03-15       Impact factor: 3.616

4.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Authors:  Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Mutations across murine hepatitis virus nsp4 alter virus fitness and membrane modifications.

Authors:  Dia C Beachboard; Jordan M Anderson-Daniels; Mark R Denison
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

7.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis.

Authors:  Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore
Journal:  Virology       Date:  2012-10-11       Impact factor: 3.616

8.  Function of the respiratory syncytial virus small hydrophobic protein.

Authors:  Sandra Fuentes; Kim C Tran; Priya Luthra; Michael N Teng; Biao He
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B.

Authors:  Ultan F Power; Hélène Plotnicky; Aline Blaecke; Thien Ngoc Nguyen
Journal:  Vaccine       Date:  2003-12-12       Impact factor: 3.641

10.  Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers.

Authors:  Hsueh-Erh Chiou; Ching-Lung Liu; Mary Jeanne Buttrey; Han-Pin Kuo; Hui-Wen Liu; Hsu-Tah Kuo; Yen-Ta Lu
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

View more
  3 in total

Review 1.  Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?

Authors:  Anna R Connell; Jeff Connell; T Ronan Leahy; Jaythoon Hassan
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

2.  Incompatible Translation Drives a Convergent Evolution and Viral Attenuation During the Development of Live Attenuated Vaccine.

Authors:  Xumin Ou; Mingshu Wang; Sai Mao; Jingyu Cao; Anchun Cheng; Dekang Zhu; Shun Chen; Renyong Jia; Mafeng Liu; Qiao Yang; Ying Wu; Xinxin Zhao; Shaqiu Zhang; Yunya Liu; Yanling Yu; Ling Zhang; Xiaoyue Chen; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Front Cell Infect Microbiol       Date:  2018-07-18       Impact factor: 5.293

Review 3.  Molecular Basis of Coronavirus Virulence and Vaccine Development.

Authors:  L Enjuanes; S Zuñiga; C Castaño-Rodriguez; J Gutierrez-Alvarez; J Canton; I Sola
Journal:  Adv Virus Res       Date:  2016-08-30       Impact factor: 9.937

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.